Case Study: Immunomedics - Pharmaceutical Technology
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Case Study: Immunomedics

Immunomedics ( is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer.

Immunomedics’ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of Antibody-Drug Conjugates (ADC).

The US Food and Drug Administration (FDA) has granted fast-track designation for sacituzumab govitecan (IMMUNO-132).

More About This Company